Stock & Company Details
Ligand Pharmaceuticals, Inc. $LGND
Price:
N/A
N/A
20M
$5.9B
52 Week High:
N/A
10 Day Average Volume:
N/A
39.74
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
LGND technical indicators
Latest Ligand Pharmaceuticals, Inc. (LGND) indicator readings as of 2026-10-09.
LGND's 14-day RSI is 54.8, in neutral territory. At $301.81 it is trading 23.5% above its 200-day moving average of $244.30, and above its 50-day average of $292.04. Price sits in the middle of its Bollinger Bands ($274.09 to $318.40). ADX reads 16.2, indicating a range-bound market rather than a trend.
LGND backtested strategy results
How 4 rule-based strategies performed on Ligand Pharmaceuticals, Inc. (LGND) over recent history, last backtested 2026-09-05. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +49.5% | 45% | 11 | -29.9% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +67.6% | 29% | 31 | -60.9% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +123.0% | 29% | 28 | -32.1% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +55.1% | 68% | 22 | -23.1% |
Overview
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Finance Bot
Ask your questions
Start by typing a question below.
